Dormant cells are replaced during Intravital systolic heart stimulation using this new technique.

Hong-Chao Ku MD PhD University of California San Francisco San Francisco Caperti Heart Vascular Institute and San Francisco Veterans Affairs Health System Richmond CA and San Francisco Headache Center San Francisco CA and oncology practice.

A major advantage of this novel Intravital systolic stimulation in patients with cancer is its potential to help repair or restore early-stage heart failure. However this procedure cannot safely be performed in all patients due to hidden risks.

In response to this challenge the UCSF scientists have developed new techniques and strategies to enhance the safety of this technique. Their researches have shown that the first significant deficits in this new technique that were not linked to hidden challenges were likely due to inherent side effects: adverse effects that did not affect patients even at high doses of the procedure. One of these potential hidden side effects is implantation of fertilized zygote.

The UCSF scientists findings are published in the Diabetes Care journal Diabetes: Clinical and Experimental Research.

UNC-Chao Ku PhD UCSF Center on Molecular Integrative Biology UCSF Health System San Francisco California and UC Davis St. George Utah USA and in other published publications.

Previous studies on induced pluripotent stem cells (iPSCs) in cardiac muscle transplantation and immuno-oncology have been performed but the incidence of serious complications in these types of IVF and the chance of serious adverse outcomes have made them hard to match.

An important aspect of this regimen is the safety of the patient. Strikingly the results of the UCSF scientists study prove the safety of their technique to be both safe and effective. UCSF doctors performed this study in collaboration with UCSF Southern California to understand the benefits of the new Intravital systolic stimulation in such patients.

The UCSF scientists studies confirm their results: no harmful side effects were observed when using Intravital systolic stimulation.

This review study should be viewed very cautiously at least by cardiology and cardiologists as its just the first step in a long process says Anne Castillo MD UCSF cardiologist and UCSF investigator. Its a proof of concept but we still need to confirm these findings in larger studies with larger patient populations.